February 27, 2009

AstraZeneca Hid Bad Studies on Seroquel; Agrees to Increase Warnings

On Thursday, AstraZeneca, the manufacturer of Seroquel, a drug used to treat certain psychological conditions, agreed as part of court proceedings on the drug, to unseal and release certain documents to the public. Bloomberg News reports that these documents indicate AstraZeneca "buried" studies which were unfavorable about the drug. More than 15,000 people treated with Seroquel are suing the company claiming it withheld information regarding the relationship between Seroquel and diabetes from physicians and patients. There are also claims that Seroquel was promoted by AstraZeneca for uses that were not approved by the FDA. With regard to the suppression of these studies, one of AstraZeneca's management is quoted as saying in an email that "The larger issue is how we face the outside world when they begin to criticize us for suppressing data." seroquel.jpg


Bloomberg News further reports that one of the unsealed documents indicated that company officials felt one of the "buried" studies was a problem because it indicated weight gain while taking the drug. Gaining weight is known to be a factor in developing diabetes. The article goes on to discuss in detail several examples of AstraZeneca either hiding important study information from the FDA or working on how to "spin" information to avoid the negative implications. Where are the ethics? These are individuals bodies and health you are dealing with. Unfortunately, more indication that too many times its about the dollars and not about providing a safe and effective medication to the public.

At this same court proceeding, Bloomberg News also reports that lawyers for AstraZeneca indicated that it had agreed to strengthen the warning regarding Seroquel's relationship to diabetes by moving it into the warnings and precautions section of the label, indicating there is a stronger link between the drug and diabetes. The litigation regarding this drug is continuing and I expect there will be further reports regarding some of the "confidential" documents which are now being made public. I will be sure to update if there is anything of significant interest.

January 16, 2009

Zyprexa, Seroquel and Risperdal Increase Risk of Heart Failure

The New York Times reports about a study published in the New England Journal of Medicine (NEJM) this week indicating that the antipsychotic drugs Zyprexa, Seroquel and Risperdal, used to treat such problems as schizophrenia, autism and dementia, double the patients risk of dying from sudden heart failure. The study indicates that the risk of death from these drugs is not high (about 3 percent in people being treated with these drugs over the past 10 years) and the risk was no different than older antipsychotic drugs. However, along with the study, an editorial was published in the NEJM suggesting doctors limit prescribing these medications, especially to children and the elderly, who are very susceptible to the problems caused by these drugs, especially weight gain issues.1034029_medicine_2.jpg


These newer antipsychotics were promoted as being safer alternatives to the older antipsychoitcs, but this study, as well as earlier studies indicate these group of drugs have significant problems of their own and they are much more expensive than the older antipsychotics. Moreover, there is some indication that these drugs are no more effective than the older, cheaper alternatives. Clearly, people with pre-existing heart conditions need to address the safety of taking these medications with their physicians.

In a related issue, Eli Lilly, the manufacturer of Zyprexa, agreed to a $1.4 billion settlement on criminal and civil charges that it illegally marketed Zyprexa by promoting its use in children and the elderly to treat "disruptive" children and to use in nursing home patients to reduce "nursing time and effort" i.e. keep the old people quiet. Zyprexa has been found in a government study to be no more effective in children than older medicines but have more serious side effects such as gaining significant amounts of weight. For a discussion of the entire sorted story of Lilly's handling of this drug, see this article in the New York Times. Lilly's side of the story, i.e. we are a good corporate citizen, can be found here.